D-1115-2018 Class II
FDA drug recall D-1115-2018 was initiated by Hetero Labs Limited Unit V on Aug 8, 2018 and is designated Class II. Reason for recall: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product. Affected quantity: 441,408 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 29, 2018
- Initiation Date
- Aug 8, 2018
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 441,408 bottles
Product description
Camber Pharmaceuticals, Inc. Valsartan Tablets, USP, 160 mg, 90 tablets Rx Only Manufactured for: Camber Pharmaceuticals, Inc. Piscataway NJ 08854 By: Hetero Hetero Labs Limited, Unit V, Pollepally Jadcherla Mahabubnagar - 509-301, India. NDC 31722-747-90 UPC 331722747905
Reason for recall
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Distribution pattern
Nationwide
Code information
All Lots with expiration dates 7/2018 to 6/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1115-2018
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026